The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Investigating the proteasome stress response as a potential novel therapeutic target in myeloma
Giada Bianchi, MD, Brigham and Women’s Hospital & Dana-Farber Cancer Institute, Boston, MA, discusses ongoing research in which a mammalian reporter cell line was developed to analyze the proteasome stress response (PSR) in multiple myeloma, and explains how this research may be used to identify novel therapeutic strategies in this disease. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
